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Minimal residual disease monitored after induction
therapy by RQ-PCR can contribute to tailor 
treatment of patients with t(8;21) 
RUNX1-RUNX1T1 rearrangement
Disease relapse still remains the most important cause of
treatment failure in childhood acute myeloid leukemia
(AML). Molecular monitoring of response to treatment by
minimal residual disease (MRD) provides important infor-
mation, widely used to tailor treatment in childhood acute
lymphoblastic leukemia.1-3 On the contrary, prognostic rel-
evance of MRD in pediatric AML has only been recently
proposed and needs to be further investigated and con-
firmed.4-6 So far, the prognostic impact of the quality of
response measured by flow cytometry after induction and
consolidation therapy has been shown to provide inde-
pendent prognostic information in pediatric AML,5 able to
permit a refinement of risk stratification and to potentially
improve AML patient outcome. 
Intense efforts have been devoted to the development of
methods able to measure residual AML burden in support
of flow cytometry, and fusion transcript detection, which is
undoubtedly useful in patient stratification at diagnosis,7 is
currently under evaluation as a suitable MRD marker to
predict relapse in AML.5 t(8;21)(q22;q22)RUNX1-
RUNX1T1 and inv(16)(p13q22)CBFB-MYH11 are recurrent
somatic lesions detected in approximately 20% of pediatric
AML at diagnosis.8 In the AIEOP AML 2002/01 protocol,
all patients carrying these abnormalities achieved morpho-
logical complete remission (CR) after the first induction
course with idarubicin, cytarabine and etoposide (ICE) and
were grouped as a unique subgroup called standard risk
(SR). These children were given, after 2 courses of ICE
induction therapy, three post-remissional courses of high-
dose cytosine-arabinoside either in combination with
etoposide (AVE cycle), or mitoxantrone (HAM cycle) or
administered alone (high-dose Ara-c).7 A larger than expect-
ed proportion of patients carrying either t(8;21) or inv(16)
relapsed, this leading to an 8-year probability of event-free
survival of 63%. Although many of the relapsing patients
were rescued by means of allogeneic hematopoietic stem
cell transplantation (HSCT),8 there is a need to identify fac-
tors able to predict patients who might not respond to con-
ventional chemotherapy to improve their outcome.9-11 
In this retrospective study, we analyzed the role of MRD
monitored by the absolute quantification of CBF fusion
transcripts early during/after induction treatment, in order
to assess its prognostic value in SR childhood AML. We
enrolled 76 of the 99 children assigned to the SR group in
the AIEOP AML 2002/01 Protocol:8 49 carried the t(8;21),
26 inv(16), and one carried the t(16;16) (see Table 1 for
details). MRD measurement on bone marrow samples col-
lected at time of diagnosis and after each of the two courses
of ICE induction chemotherapy were analyzed. It was not
possible to study the remaining 23 SR patients due to insuf-
ficient RNA extracted from cells collected after induction
courses, but the outcome of patients who were or were not
included in the study was comparable (data not shown). We
used the real-time quantitative RQ-PCR (Ipsogene
FusionQuant® kit for absolute quantification of fusions on
the ABI 7900HD; Applied Biosystems) to detect RUNX1-
RUNX1T1 and CBFB-MYH11 fusion expression following
the manufacturer’s guideline for normalization (with ABL
gene) and standard curve method for quantification (10-5
standard curve sensitivity by using plasmid serial dilutions
already included in the kit).12,13 For the t(8;21)-rearranged
patients, we found a mean number of RUNX1-RUNX1T1
fusion transcript copies at diagnosis of 643,466 (range
56,752-3,387,522); it decreased to 190,741 mean copies
after the I ICE course (range 11-3,062,045), and to 44,671
after the II ICE (range 0-1,671,638). To evaluate the impact
of MRD levels measured as copies number during sequen-
tial monitoring, the Mantel-Byar test was used to calculate
the cumulative incidence of relapse (CIR). We grouped
patients in quartiles for copy number measured at diagno-
sis, after the first and second ICE course. The number of
transcript copies at diagnosis, or after induction therapy did
not correlate with the probability of both survival and the
CIR. We then considered the logarithmic reduction of
MRD after ICE I and II courses calculated with respect to
values of copies number of transcript found at diagnosis for
each patient (Online Supplementary Table S1). We subdivid-
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Table 1. Patients’ clinical characteristics. 
t(8;21) % inv(16) %
Patients 49 27
Sex
M 27 55.1 15 55.5
F 22 44.9 12 44.5
Age, years
< 1 0 0 2 7.4
1-2 0 0 2 7.4
2-10 26 53.1 7 26 
> 10 23 46.9 16 59.2
WBC (x109/L)
< 20 16 32.6 7 26
20-100 28 57 18 66.6
≥ 100 5 10.4 2 7.4
Outcome
Relapse 9 18.4 6 22.2 
RC post relapse 8 16.3 6 22.2
Death during/ 4 8.2 0 0
post-salvage therapy
Death after relapse 2 4.1 0 0
Figure 1. Overall survival (OS) in RUNX1-RUNX1T1 patients subdi-
vided into three classes of MRD log reduction after two induction
courses.
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ed patients in three Log-reduction groups: patients who
reduced MRD less than 2 Log, between 2 and 3 Log, and
those who reduced more than 3 Log in order to investigate
whether this distribution into groups for MRD reduction
was able to predict a different relapse risk. We interestingly
found that 21 (43%) out of the 49 t(8;21) patients enrolled
had a slow clearance of blasts after I ICE (<2 Log with
respect to diagnosis), and, at the end of the II ICE course,
10 of them still had an MRD reduction lower than 2 Log.
These slow-responding t(8;21) patients at the end of the
two induction courses had a worse prognosis when com-
pared to patients who reduced MRD more than 3 Log
(patients who reduced less than 2 Log showed a 10-year
OS of only 58.3% compared to 85.6% of patients who
reduced more than 3 Log (P=0.2) (Figure 1). Next, we inves-
tigated if MRD might influence the risk of relapse. Nine out
of the 49 patients with t(8;21) relapsed at a median time of
225 days (range 76-469) from diagnosis: 7 of the 9 relapsed
t(8;21) patients reduced MRD less than 2 Log after I ICE,
and 5 of these 9 relapsed patients still reduced MRD less
than 2 Log at the end of the II induction course. The 10-
year CIR of these patients after the two induction courses
was significantly higher (50%) than that of patients with an
MRD reduction greater than 2 Log (17% for 2-3 Log MRD
reduction, and 9% for MRD Log reduction >3; I ICE
P=0.02; 1B II ICE P=0.004) (Figure 2A). In univariate analy-
sis both MRD Log reduction after induction therapy and
white blood cell (WBC) count at diagnosis more than
100,000, as recently reported,8 were significant independ-
ent factors predicting leukemia relapse; however, they
were not confirmed in multivariate analysis, probably due
to the limited sample size analyzed. In view of these data,
we show that monitoring of molecular MRD levels is
instrumental to predict the risk of relapse for t(8;21)-
rearranged patients, thus providing important prognostic
information for the therapeutic management of these chil-
dren.
We then considered inv(16)-rearranged patients and per-
formed similar analyses for the 27 patients enrolled. These
patients showed a mean number of transcript copies at
diagnosis of 143,015 (range 102-582,426), which decreased
to 631 (range 0-3726) after the I ICE, and to 190 (range 0-
686) after the II ICE course, respectively. We evaluated if
the copy number of fusion transcripts distributed in quar-
tiles found in BM of patients at diagnosis, and at the end of
the two ICE courses may have a prognostic value, but no
significant differences were identified either for CIR or for
OS in inv(16) rearranged patients (Online Supplementary
Figure S1). Furthermore, by using the Log MRD reduction
distribution, we found that 21 of 27 patients (78%) after
the I ICE, and 24 of 27 (89%) after the II ICE achieved an
MRD reduction greater than 2 Log. At time of last follow
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Figure 2. Cumulative incidence of relapse (CIR) in patients with RUNX1-RUNX1T1 (A) and CBFB-MYH11 (A) subdivided into different sub-
groups according to MRD log reduction after I ICE and II ICE.
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up, 6 of 27 patients had relapsed; among them, we docu-
mented that MRD was reduced more than 2 Log since the
end of I ICE. We conclude that the CBFB-MYH11 AML
showed in most cases a rapid clearance of blasts after
induction therapy. Thus, early MRD monitoring does not
seem to be useful for predicting relapse occurrence (not sig-
nificant at 10 years) (Figure 2B). 
Through this analysis, we document that among pedi-
atric Core Binding Factor-rearranged AML, two different
patterns of molecular response after induction therapy with
a different capacity of predicting relapse can be identified.
In particular, we found that monitoring of MRD levels after
induction provides a reliable prognostic parameter exclu-
sively for the RUNX1-RUNX1T1-rearranged patients.
These data confirm the clinical usefulness of monitoring
MRD levels reported in a recent study on adults with
RUNX1-RUNX1T1AML,14  although this report differs from
our analysis in both timing (after 2 courses of consolidation
therapy) and levels of MRD (3 Log reduction) cutoff sug-
gested to predict relapse. 
In view of these results, we propose a novel MRD-direct-
ed risk stratification and treatment of t(8;21) slow-respon-
ders to induction therapy. These children can be identified
early during treatment and, in the light of their high risk of
relapse, can be considered candidates to more aggressive
therapies, even including allogeneic HSCT. We therefore
propose that RQ-PCR MRD monitoring complemented
with the flow-cytometry MRD14 data might be incorporat-
ed directly into clinical practice of the RUNX1-RUNX1T1
risk class attribution, whereas further studies on extended
MRD monitoring for CBFB-MYH11 rearranged patients are
warranted to identify a possible role in predicting the risk
of late relapse.
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